Clozapine-associated neutropenia following augmentation with sodium valproate
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- 2050313x211019791
Final published version, 117 KB, PDF document
Clozapine is gold standard for the management of treatment-resistant schizophrenia. It can offer life-changing symptom reduction where other antipsychotics have failed, and for these patients, treatment with clozapine should be maintained, if in any possible way. However, treatment with clozapine comes with a risk of developing potentially fatal adverse reactions, for example, severe neutropenia or agranulocytosis, in which case, treatment must be discontinued. Here, we present a case of clozapine-related neutropenia that commenced after the addition of sodium valproate. A subsequent re-challenge to clozapine resulted in severe neutropenia and led to the permanent cessation of clozapine treatment. The patient had been tolerating clozapine for more than a year before the addition of sodium valproate. The awareness of an interaction between clozapine and sodium valproate could help reduce the risk of clozapine-induced neutropenia and subsequent clozapine discontinuation.
Original language | English |
---|---|
Journal | Sage Open Medical Case Reports |
Volume | 9 |
Number of pages | 3 |
ISSN | 2050-313X |
DOIs | |
Publication status | Published - 2021 |
Bibliographical note
Publisher Copyright:
© The Author(s) 2021.
- adverse reaction, agranulocytosis, Clozapine, drug interaction, neutropenia, valproate
Research areas
ID: 272237020